Answers are grounded in this paper and cite their sources.
Identifies barriers and facilitators influencing SGLT2 inhibitor adoption, suggesting systematic targets to enhance uptake of guideline-directed therapies.
This study highlights different themes to the barriers and facilitators of using SGLT2 inhibitors in British Columbia. The identification of these barriers provides a specific target for improvement, and the facilitators can be leveraged for the increased use of SGLT2 inhibitors. Efforts to address and optimize these barriers and facilitators in a systematic approach may lead to an increase in the use of these efficacious medications.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: